Coherus Oncology (CHRS) Income towards Parent Company (2013 - 2026)

Coherus Oncology has reported Income towards Parent Company for 14 years, with the latest figure at -$1.4 million in Q1 2026.

• Quarterly Income towards Parent Company rose 84.82% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $358.9 million (up 452.16% YoY) and the FY2025 annual result came in at $351.1 million, up 43.97% from the prior year.
• Income towards Parent Company slipped to -$1.4 million in Q1 2026 per CHRS's latest filing, from $8.7 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $342.6 million in Q2 2025 and troughed at -$96.1 million in Q1 2022.
• A 5-year average of $3.8 million and a median of -$9.2 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company plunged 124.9% in 2022, then soared 717.15% in 2025.
• Over 5 years, Income towards Parent Company stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then soared by 94.22% to -$4.6 million in 2024, then soared by 289.09% to $8.7 million in 2025, then sank by 115.99% to -$1.4 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.4 million, $8.7 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.